NuCana NUC-7738 combo: 3% viability in two myeloma models
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NuCana plc (NCNA) reported preclinical tests found NUC-7738 enhanced carfilzomib activity in multiple myeloma cell lines. The combination left 3% of cells viable in two models and 26% in a third after 96 hours, at concentrations where each agent alone left approximately half viable. In two models, the combination’s activity exceeded what was expected if the agents acted independently; in the third, the effect was additive.
In one model, proteasome activity was 25% of untreated control with the combination, versus 52% with carfilzomib alone after 24 hours. A separate screen found greater-than-expected combination activity in 28 of 33 solid-tumor models spanning 14 tumor types; carfilzomib ranked first among 70 partner drugs on that measure. NuCana said further studies are needed to test the proposed mode of action and assess its relevance to treatment in patients. The company plans to present final Phase 2 expansion-cohort results at a congress in London from December 14–16, 2026.
Filing Explained
NuCana says it anticipates its cash resources will fund planned operations into
Key Figures
Key Terms
proteasome inhibitor medical
NFE2L1 technical
ProTide technology technical
nucleoside analogs medical
RNA polyadenylation medical
thymidylate synthase medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NUC-7738 and carfilzomib do in NCNA’s multiple myeloma cell-line tests?
How broad was NCNA’s NUC-7738 combination screen?
When will NCNA present its final NUC-7738 Phase 2 expansion-cohort results?
How long does NCNA expect its cash resources to fund planned operations?
AI-generated analysis. How Rhea-AI works. Not financial advice.